Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases
A technology based on residues and basic structures, applied in smaller molecules and easy fields, can solve problems such as changes in cell proliferation and cytokines
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0065] Inhibitory characteristics of new inhibitors of dipeptidyl peptidase IV
[0066] In the following tables (Tables 1 to 14) new inhibitors are summarized, for which the inventors have shown that these substances are capable of inhibiting dipeptidyl peptidase IV and enzymes with similar effects in enzymatic activity. Inhibition characteristics were measured as IC-50 values or ID 50 values (the latter marked with "*") for the enzymes in question. Via fluorescent substrate (Ala-Pro) 2 -Rhodamine 110 to measure enzyme activity.
[0067] Table 1
[0068]
[0069] Table 2
[0070]
[0071]
[0072] table 3
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092] Table 4
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[...
Embodiment 2
[0200] Combined inhibition of dipeptidyl peptidase IV and similarly acting enzymes and alanyl aminopeptidase and similarly acting enzymes against experimental autoimmune encephalomyelitis (EAE) in mice, an animal model of multiple sclerosis treatment effect
[0201] The disease EAE was induced by daily injection of PLP139-151 (myelin antigen protein lipoprotein peptide 139-151) to SJL / J mice (n=10). Following disease onset, which is day 11 after immunization, therapeutic intervention was performed by intraperitoneal injection of 1 mg of each peptidase inhibitor on the first day and a further injection of 0.5 mg of each inhibitor every other day. Disease scores are defined by clearly varying degrees of paralysis [vD1]. Healthy animals have a disease score of 0. Actinonine is used as alanyl aminopeptidase inhibitor, Lys[Z(NO 2 )] pyrrolidine anhydride (pyrrolidide) is used as a dipeptidyl peptidase IV inhibitor. Treatment was performed 46 days after immunization. The result...
Embodiment 3
[0203] Combined inhibition of dipeptidyl peptidase IV and similarly acting enzymes and alanyl aminopeptidase and similarly acting enzymes against dextran sulfate-induced colitis (an animal model of chronic inflammatory disease of the small intestine) in mice treatment effect
[0204] Primary colon-associated inflammation (a disease equivalent to human ulcerative colitis) was induced in 8-week-old female Balb / c mice by administration of 3% dextran sodium sulfate dissolved in drinking water. After three days, all animals showed obvious symptoms typical of the disease. Peptidase inhibitors (or phosphate-buffered saline as placebo) were administered intraperitoneally from day 5 for three consecutive days. The extent of disease is determined according to a known rating system (score). When determining the score, the following parameters were considered: consistency of the stool (solid = 0 points (pts.); mushy = 2 pts.; liquid / as diarrhea = 4 pts.); detection of blood in the stool...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com